List of Excipients in Branded Drug ZANTAC 150

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
JC World Bell Wholesale Co Inc	ZANTAC 150	ranitidine	50269-220	CELLULOSE, MICROCRYSTALLINE
JC World Bell Wholesale Co Inc	ZANTAC 150	ranitidine	50269-220	FERRIC OXIDE RED
JC World Bell Wholesale Co Inc	ZANTAC 150	ranitidine	50269-220	HYPROMELLOSES
JC World Bell Wholesale Co Inc	ZANTAC 150	ranitidine	50269-220	MAGNESIUM STEARATE
JC World Bell Wholesale Co Inc	ZANTAC 150	ranitidine	50269-220	TITANIUM DIOXIDE

Zantac 150 Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

ZANTAC 150 is the historical immediate-release ranitidine hydrochloride tablet containing the equivalent of 150 mg ranitidine. Its commercial value was built on OTC brand recognition, low-cost tablet manufacture, and broad gastrointestinal indications. The core commercial constraint is not conventional patent expiry. It is ranitidine’s association with the nitrosamine impurity N-nitrosodimethylamine, or NDMA. FDA requested removal of all ranitidine products from the U.S. market in 2020 because NDMA levels could increase during storage and under elevated temperatures.[1]

An investable ZANTAC 150 strategy therefore requires a reformulated product with validated nitrosamine control, a clear FDA pathway, strong packaging and stability data, and differentiation against famotidine-based products such as Zantac 360. Historical ZANTAC 150 excipients are technically straightforward and largely unprotectable today. The higher-value opportunity is a compliant ranitidine formulation, manufacturing process, or delivery system that can support a new regulatory filing and reliable shelf life.

What is ZANTAC 150 and what excipients does it contain?

ZANTAC 150 historically was an immediate-release oral tablet containing ranitidine hydrochloride equivalent to 150 mg of ranitidine. The product was sold for heartburn and other acid-related gastrointestinal symptoms.

Historical U.S. label versions identified inactive ingredients including:

Excipient category	Historical excipients or functions
Diluent and compression aid	Microcrystalline cellulose
Disintegrant	Croscarmellose sodium
Lubricant	Magnesium stearate
Film coating	Hypromellose, titanium dioxide, triacetin
Colorant	Product-specific colorants, including iron oxide in some presentations

The precise excipient list varied by manufacturer, strength, country, and packaging configuration. DailyMed labeling should control for any specific historical lot or sponsor presentation.[2]

The formulation was commercially efficient because it used standard immediate-release tablet technology. No complex modified-release system, enteric coating, liquid vehicle, or device was necessary.

What is the excipient strategy for a new ZANTAC 150 formulation?

The excipient strategy should treat moisture, heat, pH, oxygen exposure, and packaging as an integrated control system. Excipients alone cannot be assumed to prevent NDMA formation from ranitidine.

Control moisture and local microenvironments

The formulation should minimize water activity and avoid excipients that introduce uncontrolled moisture or create localized acidic or basic microenvironments. Candidate approaches include:

• Low-moisture direct-compression excipients.
• Tight control of excipient loss on drying.
• Selection of low-peroxide grades where oxidative degradation is relevant.
• Reduced use of hygroscopic materials unless they provide a clear manufacturing benefit.
• Validated control of granulation water if wet granulation is used.

Microcrystalline cellulose and croscarmellose sodium are familiar and scalable choices, but their grade, moisture profile, particle size, and supplier controls matter. The relevant development question is not whether an excipient is listed in the historical product. It is whether the selected grade maintains impurity control through manufacture and shelf life.

Evaluate pH and chemical compatibility

Ranitidine degradation can be affected by the local chemical environment. Formulators should screen excipients and coating systems for:

• Acidic or basic residues.
• Reactive carbonyl compounds.
• Peroxides and other oxidizing impurities.
• Nitrite contamination.
• Interaction with coating polymers, colorants, and adhesives.
• Compatibility under accelerated temperature and humidity.

Nitrite control deserves specific attention because nitrosamine risk assessments commonly examine nitrosating species, amine-containing drug substances, excipients, process water, and packaging components. FDA’s nitrosamine guidance supports a risk-based evaluation of drug substance, drug product, manufacturing process, and storage conditions.[3]

Use packaging as a formulation control

A robust package may provide more commercial value than a minor tablet composition change. Development options include:

Packaging option	Commercial and technical role
High-barrier blister	Limits moisture and oxygen exposure; supports unit-dose compliance
Alu-Alu blister	Provides stronger barrier protection than conventional PVC-based blister systems
HDPE bottle with desiccant	Familiar OTC format; requires validated moisture ingress control
Unit-dose sachet or pouch	Supports pharmacy and travel use; may increase packaging cost
Child-resistant bottle	Supports OTC regulatory requirements where applicable

The package should be evaluated with the final tablet, not as a separate development exercise. Stability protocols should measure ranitidine assay, degradation products, NDMA, dissolution, hardness, friability, water activity, and appearance.

What excipients are most commercially attractive?

The best commercial excipient platform is unlikely to depend on a single novel excipient. A low-risk strategy uses established compendial materials but creates value through composition, process control, impurity specifications, and package integration.

Priority excipient attributes

1. Low moisture and low nitrite burden.
2. Low peroxide and low reactive impurity profile.
3. Reliable global supply from multiple qualified vendors.
4. Direct-compression performance at the 150 mg strength.
5. Compatibility with film coating and high-barrier packaging.
6. Consistent dissolution after long-term storage.
7. Regulatory familiarity in the United States and major international markets.

A formulation using standard excipients may be easier to approve but harder to protect. A sponsor seeking intellectual property should focus on a reproducible combination of excipient specifications, manufacturing controls, packaging, and impurity outcomes rather than simply substituting one common diluent for another.

What formulation patents could protect a ZANTAC 150 product?

Historical ZANTAC 150 tablet patents are unlikely to create a meaningful barrier today because ranitidine has been off-patent for many years. The original ranitidine compound and conventional immediate-release tablet concepts are not commercially defensible as new inventions merely because they are used in a new product.

Potentially protectable subject matter may include:

• A composition that limits NDMA formation during storage.
• Defined nitrite and peroxide limits for excipients.
• A moisture-controlled tablet and package combination.
• A specific granulation or drying process.
• A low-water-activity formulation.
• A stability profile demonstrated under defined temperature and humidity conditions.
• A dosage form with improved dissolution or reduced degradation.
• A manufacturing process that reduces nitrosamine formation.
• A combination of formulation, blister configuration, and shelf-life specification.

Patent strength would depend on demonstrated technical effect. A claim covering “ranitidine plus conventional tablet excipients” would face substantial validity risk if similar formulations were publicly known. A claim tied to defined impurity limits, process parameters, and unexpected stability results would be more defensible.

When did ZANTAC 150 lose exclusivity?

Ranitidine lost meaningful U.S. small-molecule exclusivity decades ago. The active ingredient was widely marketed by generic manufacturers before FDA’s 2020 withdrawal action.

Event	Timing and significance
Original ranitidine development	Late 1970s
U.S. prescription launch of Zantac	1980s
Generic ranitidine availability	Established before the 2000s
OTC ZANTAC 150 commercialization	Broadly marketed before 2020
FDA request to withdraw ranitidine	April 2020
Market consequence	U.S. ranitidine products were removed pending resolution of NDMA concerns

The commercial issue is therefore market re-entry, not extension of the original exclusivity period. A newly approved formulation could receive regulatory exclusivity associated with a new application or qualifying innovation, but ordinary ranitidine tablets would not receive meaningful protection from old compound patents.

What is the FDA regulatory status of ZANTAC 150?

FDA requested that manufacturers withdraw all prescription and OTC ranitidine products from the U.S. market in April 2020.[1] The agency’s action followed testing showing that NDMA levels could increase over time and at higher storage temperatures.

This regulatory history affects every new U.S. ranitidine strategy:

• A sponsor cannot rely on the historical OTC monograph position.
• A new product must address the NDMA risk through current FDA requirements.
• Stability data must be generated on the final commercial formulation and package.
• Drug substance, excipients, manufacturing conditions, and storage must be assessed together.
• A previous ZANTAC label does not establish regulatory acceptability for a new product.

The current commercial reference point in the U.S. OTC acid-reducer market is not historical ranitidine. It is famotidine-based Zantac 360 and competing H2-receptor antagonist products. Famotidine products do not create a direct substitute for a ranitidine regulatory filing, but they materially affect pricing, consumer expectations, and retailer shelf allocation.

Does ZANTAC 150 have Orange Book or Paragraph IV significance?

Historical ZANTAC 150 products were associated with approved ranitidine applications, but the commercial relevance of those listings changed after the 2020 withdrawal action. Orange Book status must be evaluated by specific application, dosage form, and current marketing status rather than by brand name alone.[4]

For a new ranitidine tablet:

• A Paragraph IV strategy would target listed patents associated with the relevant reference product, if any remain listed and applicable.
• A formulation sponsor could use Paragraph IV certification against composition or method-of-use patents.
• A sponsor could also pursue a 505(b)(2) pathway if the product relies partly on prior findings but introduces a new formulation, package, or delivery system.
• A fully generic strategy would require an approved reference product and a legally usable ANDA pathway.

Because the central historical issue was product withdrawal for NDMA risk, the main barrier is likely technical and regulatory validation rather than an active blocking patent estate.

What commercial opportunities exist for ZANTAC 150 excipient technology?

Reformulated ranitidine tablets

The largest opportunity would be a U.S. or international ranitidine product with strong long-term NDMA data, scalable manufacturing, and an established OTC brand or private-label partner. Commercial success would depend on regulatory clearance, retailer acceptance, and consumer trust.

Private-label and retailer products

Retailers may value a compliant ranitidine alternative if it offers:

• A low-cost tablet format.
• Unit-dose blister packaging.
• Clear storage instructions.
• Stable supply of qualified excipients.
• A credible impurity-control package.
• A price advantage over branded famotidine products.

The private-label opportunity is more likely to favor a contract development and manufacturing organization, or CDMO, with validated nitrosamine controls than an excipient supplier acting alone.

Excipient supply and specification packages

Excipient manufacturers can create value through qualified low-nitrite, low-peroxide, low-moisture grades supported by:

• Supplier qualification dossiers.
• Lot-release testing.
• Change-control commitments.
• Regulatory support.
• Compatibility data with ranitidine.
• Stability data in relevant packaging.

This model may produce recurring revenue without owning the finished drug application.

Contract manufacturing

A CDMO could offer a bundled service covering formulation development, low-moisture processing, analytical testing, high-barrier packaging, and stability management. The strongest differentiation would come from process capability and data, not from ordinary tableting capacity.

Non-U.S. markets

Ranitidine regulatory treatment varies by jurisdiction. Some markets may permit products under different conditions, while others may maintain restrictions or require new evidence. Geographic expansion should be based on country-specific regulatory status, pharmacopoeial requirements, import rules, and available reference products.

How does ZANTAC 150 compare with famotidine products?

Factor	Historical ZANTAC 150	Famotidine-based products
Active ingredient	Ranitidine	Famotidine
Dosage form	Immediate-release tablet	Immediate-release tablet, chewable and other forms
Main regulatory issue	NDMA-related withdrawal	Conventional generic and OTC competition
Excipients	Standard tablet and film-coating system	Broad range of standard OTC excipients
Patent position	Legacy exclusivity expired	Product-specific and generally mature generic landscape
Re-entry barrier	New evidence and regulatory acceptance	Established market access
Commercial advantage	Strong historical brand recognition	Current market availability and lower regulatory risk

The brand name alone does not recreate the historical ranitidine franchise. ZANTAC 360 uses famotidine and should be analyzed as a separate product and patent estate.

What manufacturing and intellectual-property barriers exist?

The principal manufacturing barriers are:

• Controlling nitrite and peroxide inputs.
• Preventing degradation during wet processing and drying.
• Maintaining low moisture through compression and coating.
• Demonstrating stability in the final package.
• Producing sensitive analytical data at low detection levels.
• Managing supplier changes without destabilizing the product.

The principal IP barriers are narrower:

• Existing patents covering a successfully reformulated ranitidine composition.
• Process patents tied to impurity reduction.
• Packaging claims linked to demonstrated stability.
• Method-of-use claims for approved indications.
• Trade secrets covering raw-material specifications and process controls.

A patent estate built only around standard excipients would be weak. A portfolio combining composition claims, process claims, packaging claims, and manufacturing know-how would provide stronger commercial protection.

What generic launch scenarios exist for a ZANTAC 150 successor?

Scenario 1: Conventional generic ranitidine

This is the lowest-cost formulation but carries the highest regulatory and commercial risk. Historical tablet technology is easy to reproduce, yet it does not address the central NDMA issue.

Scenario 2: Reformulated prescription product

A sponsor could pursue a new application supported by extensive chemistry, manufacturing, and controls data. This route may justify stronger formulation and process patents but requires substantial development investment.

Scenario 3: OTC brand relaunch

A brand owner could seek to re-establish ZANTAC consumer recognition with a validated ranitidine product, subject to FDA acceptance and labeling requirements. The investment would include regulatory work, consumer education, retailer negotiations, and post-market surveillance.

Scenario 4: Famotidine brand extension

The commercially safer route is to use ZANTAC branding with famotidine, as reflected by Zantac 360. This avoids ranitidine’s NDMA history but does not create a ranitidine excipient opportunity.

Key Takeaways

• ZANTAC 150 was a conventional immediate-release ranitidine hydrochloride tablet containing 150 mg ranitidine equivalent.
• Its historical excipient system used standard materials such as microcrystalline cellulose, croscarmellose sodium, magnesium stearate, hypromellose, titanium dioxide, and triacetin.
• The central development problem is NDMA control during manufacture and storage, not tablet compression.
• A viable formulation should combine low-risk excipients, tight nitrite and peroxide controls, low moisture, validated processing, and high-barrier packaging.
• Conventional historical ZANTAC 150 excipients offer limited patent value.
• Stronger protection may come from formulation-process-package combinations supported by stability data.
• The U.S. commercial opportunity depends on a new regulatory pathway after FDA’s 2020 ranitidine withdrawal request.
• Famotidine-based Zantac 360 is a direct commercial competitor but is not a ranitidine product.
• Excipient suppliers and CDMOs may capture value through qualified low-impurity materials, testing, and integrated manufacturing services.
• A generic launch based solely on historical ranitidine tablet technology has a weak risk-adjusted profile.

FAQs

Can the original ZANTAC 150 excipient formula be relaunched?

Not on the historical formulation alone. A U.S. relaunch would need to address the NDMA-related regulatory history and demonstrate product quality and stability under current FDA requirements.

Which excipient is most important for reducing ranitidine NDMA risk?

No single excipient can be identified as a standalone solution. The relevant controls include excipient nitrite and peroxide levels, moisture, pH environment, processing conditions, packaging, and storage stability.

Is microcrystalline cellulose suitable for a ranitidine tablet?

Microcrystalline cellulose is technically suitable for immediate-release tablet manufacture, but the selected grade must be assessed for moisture, impurities, compatibility, and stability in the complete formulation.

Could a high-barrier blister create patentable value?

It could support patent claims if the package-formulation combination produces a demonstrated reduction in degradation or extends shelf life. Packaging alone would not necessarily provide strong patent protection.

Is Zantac 360 the same product as ZANTAC 150?

No. Historical ZANTAC 150 contained ranitidine. Zantac 360 is associated with famotidine-based products and should be analyzed separately for regulatory, formulation, patent, and commercial purposes.

References

1. U.S. Food and Drug Administration. (2020, April 1). FDA requests removal of all ranitidine products from the market. https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-market

2. National Library of Medicine. (n.d.). DailyMed: Zantac 150 ranitidine hydrochloride tablet labeling. https://dailymed.nlm.nih.gov/

3. U.S. Food and Drug Administration. (2024). Control of nitrosamine impurities in human drugs: Guidance for industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/control-nitrosamine-impurities-human-drugs

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book